Letter: Columnists have rushed to judgment of CBD (www.dispatch.com)

  • Op-ed columnists Benton Bodamer and Rachel Friedman provided their views on the regulation of cannabidiol in Sunday’s Dispatch.
  • Only 8 percent of investigational drugs that start testing in humans become FDA-approved.
  • Over many decades, the experience of those in medicine has shown that anecdotes and appeals to popularity have misled many and harmed patients.
  • Anecdotes which represent coincidence but pass for causation fall far short of this standard and do not provide a comprehensive picture.